Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medico-economic evaluation of fluorescence-guided surgery for optimization of glioblastoma resection (RESECT)
2011-005838-19Phase 3Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of 5-aminolevulinic acid in glioblastoma (GBM) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Complete surgical excision rate. Started May 2013; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2011-005838-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005838-19.